The Gram-positive bacterium Listeria monocytogenes (Lm) is an emerging platform for
cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer …

Strategies to augment immunity to self/neoantigens expressed by cancers are urgently
needed to expand the proportion of patients benefiting from immunotherapy, particularly for …

Abstract Purpose of Review Immunotherapy has emerged as a promising cancer treatment;
however, success in only select clinical indications underscores the need for novel …

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality despite efforts
to improve standard interventions. As CRC patients can benefit from immunotherapeutic …

Listeria monocytogenes, a facultative intracellular bacterium, can induce a potent antitumor
immune response if engineered to express a model tumor antigen also expressed by the …

Active immunotherapy targeting dendritic cells (DCs) has shown great promise in preclinical
models and in human clinical trials for the treatment of malignant disease. Sipuleucel-T …

Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a
popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed …

The efficacy and potency of Listeria monocytogenes (LM)-based cancer vaccines are
intricately influenced by the dynamic interplay between the host and pathogen. LM has …

Simple Summary Despite their potential and promising anti-tumor efficacy, previously
developed cancer vaccines targeting different tumor-associated antigens for colorectal …